References
- LeuchtSCorvesCArbterDSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisLancet2009373314119058842
- GentileSA systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazoleNeuropsychiatr Dis Treat2009511712519557106
- HogartyGESchoolerNRBakerRWEfficacy versus effectivenessPsychiatr Serv19974811079285969
- LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med20053531209122316172203
- StroupTSLiebermanJAMcEvoyJPEffectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE studyAm J Psychiatry200716441542717329466
- ColeyKCFabianTJKimEPredictors of aripiprazole treatment continuation in hospitalized patientsJ Clin Psychiatry2008691393139719012819
- GorwoodPMeeting everyday challenges: antipsychotic therapy in the real worldEur Neuropsychopharmacol20061651565162
- BurrisKDMolskiTFXuCAripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptorsJ Pharmacol Exp Ther200230238138912065741
- JordanSKoprivicaVChenRThe antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptorEur J Pharmacol200244113714012063084
- HiroseTUwahodoYYamadaSMechanism of action of ariprazole predicts clinical efficacy and a favorable side-effect profileJ Psychopharmacol20041837538315358981
- ChungAKChuaSEEffects on prolongation of Bazett’s corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysisJ Psychopharmacol20112564666620826552
- BergmanFZacherANassAPsychosocial functioning in patients with schizophrenia treated with aripiprazole – an office-based real-world setting. Results from the German post-marketing surveillance studyPharmacopsychiatry20094210110819452378
- MarderSRMcQuadeRDStockEAripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo-controlled trialsSchizophr Res20036112313612729864
- KaneJMCarsonWHSahaAREfficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorderJ Clin Psychiatry20026376377112363115
- TandonRMarcusRNStockEGA prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patient with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)Schizophr Res200684778916483745